Project Grant HT94252510663
Award Date
9/30/25
Completion Date
9/29/29
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The Defense Health Agency awarded a $533,308 project grant to the Sloan-Kettering Institute for Cancer Research in New York, NY under the Military Medical Research and Development (CFDA 12.420) program. The grant, which runs from September 1, 2025 to August 31, 2029, will support integrated immunomodulatory analysis of LAG3 inhibition in renal cell carcinoma. The Sloan-Kettering Institute, a leading nonprofit cancer research institution, will conduct advanced biomedical research aimed at...
The Defense Health Agency awarded a $619,500 Project Grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization in New York, NY. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program and will support research to investigate the immunogenicity and targeting of shared neoantigens in adenoid cystic cancer over a 3-year period from September 1, 2023 to August 31, 2026. The research aims to transform health care for Service...
Sloan-Kettering Institute For Cancer Research was awarded a $796,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 15, 2023 through July 14, 2026. The grant will support research to develop novel tools to improve responses to DNA-damaging therapeutics in metastatic breast cancer. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise in cancer biology,...
The Sloan-Kettering Institute for Cancer Research was awarded a $707,346 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2024, supports Sloan-Kettering's cancer research initiatives, including investigations into the tumor microenvironment, mechanisms of metastasis, epigenetic alterations in cancer, resistance to cancer therapies, aging-related biology, and hematologic malignancies....
The Defense Health Agency awarded a $923,805 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research in New York. The grant supports a 3-year research project titled "Systematic Functional Dissection of Cancer Cell States in Lung Tumors" starting September 1, 2025. The grant aims to conduct advanced biomedical research to transform healthcare for military service members, veterans, and the broader...
Sloan-Kettering Institute For Cancer Research was awarded a $845,789 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 1, 2023 to June 30, 2026. The grant will support research to discover biomarkers and address outcome disparities for prostate cancer through exploiting real-world clinical genomic data. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise...
The Defense Health Agency has awarded a $1,387,727 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma", will fund research aimed at transforming healthcare for military service members, veterans, and the broader public. The research will investigate innovative approaches to cancer diagnosis,...
The Sloan-Kettering Institute for Cancer Research was awarded a $1,295,691 Project Grant on November 1, 2024 under the Military Medical Research and Development (CFDA 12.420) federal grant program, administered by the Defense Health Agency. The funding will support research aimed at "Targeting Hypermethylation to Overcome Cisplatin Resistance in Patients with Relapsed/Refractory Germ Cell Tumors" over a performance period ending on October 31, 2027. As a leading comprehensive cancer...
The Defense Health Agency awarded a $352,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "AUGMENTING IN VIVO EFFICACY OF A NOVEL LANOSTEROL SYNTHASE INHIBITOR IN GLIOBLASTOMA", will support advanced biomedical research to investigate innovative treatments for glioblastoma, a type of brain cancer. The research, spanning from September 2025 to August 2027, aims to...
This $664,456 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research. The award will fund a 3-year research project focused on investigating biomarkers of immune response in mismatch repair-deficient (MMR-D) endometrial cancer treated with immune checkpoint blockade and radiation. The research aims to advance the understanding of cancer immunology and develop new...